Cargando…
LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study
Autores principales: | Bersanelli, M., Giannarelli, D., Verzoni, E., Buti, S., De Giorgi, U., Clemente, A., Filetti, M., Di Napoli, M., Calvetti, L., Ermacora, P., Catino, A.M., Guaitoli, G., Bonomo, P., Mazzoni, F., Veccia, A., Grosso, F., Maruzzo, M., Rossi, E., Grossi, F., Procopio, G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506488/ http://dx.doi.org/10.1016/j.annonc.2020.08.2323 |
Ejemplares similares
-
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)
por: Bersanelli, Melissa, et al.
Publicado: (2021) -
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
por: Bersanelli, Melissa, et al.
Publicado: (2023) -
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis
por: Anpalakhan, Shobana, et al.
Publicado: (2023) -
L'Invidia /
por: Olesha, I︠U︡riĭ Karlovich, 1899-1960 -
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
por: Bersanelli, Melissa, et al.
Publicado: (2020)